MDS (Myelodysplastic Syndrome)NCT07561385
Dresden MDS Registry With an Accompanying Biomaterial Collection
An observational study of MDS (Myelodysplastic Syndrome) and MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome, run by Technische Universität Dresden at 1 site in Germany.
Trial summary
A registry for the study of the epidemiology, clinical course, and progression of myelodysplastic neoplasms (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN overlap syndromes), and their precursor syndromes (CHIP, CCUS) Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- MDS (Myelodysplastic Syndrome), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome, CHIP
- How many people
- 500 participants
- Where
- 1 siteGermany
- Study dates
- Sep 2026to Jun 2036
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Diagnosis of myelodysplastic syndrome (MDS), MDS/MPN overlap syndrome, or evidence of a myelodysplastic precursor syndrome, defined as clonal hematopoiesis without cytopenia (clonal hematopoiesis of indeterminate potential, CHIP) or clonal hematopoiesis with cytopenia (clonal cytopenia of undetermined significance, CCUS) according to current WHO criteria
Who may be able to join
- Diagnosis of myelodysplastic syndrome (MDS), MDS/MPN overlap syndrome or evidence of myelodysplastic precursor syndrome, defined as clonal haematopoiesis without cytopenia (clonal haematopoiesis of indeterminate potential, CHIP) or clonal haematopoiesis with cytopenia (clonal cytopenia of undetermined significance, CCUS) in accordance with current WHO criteria
- Age ≥18 years
- Submission of a signed consent form for participation in the MDS Registry
Who cannot join
- No exclusion criteria have been established with regard to the registry's primary objective. In particular, patients with comorbidities and those receiving non-curative treatment may be explicitly included in order to provide a realistic picture of actual care practices
- Inclusion in the registry is excluded in cases where a written consent form is not available or where patients are unable to understand the nature and implications of participating in this registry
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ekaterina Balaian, Dr. med. contact
Germany1 site
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, 01307
Katja Sockel, Dr. med., +493514580, Katja.Sockel@ukdd.de
Ekaterina Balaian, Dr. med.
About this study
A registry for the study of the epidemiology, clinical course, and progression of myelodysplastic neoplasms (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN overlap syndromes), and their precursor syndromes (CHIP, CCUS)
- Conditions
- MDS (Myelodysplastic Syndrome), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome, CHIP, CCUS Clonal Cytopenia of Undetermined Significance
- Medical subject headings
- Anemia, Refractory, with Excess of Blasts
What is being measured
The primary outcome is the main question the study is designed to answer.
Collection of epidemiological data on MDS, MDS/MPN overlap syndromes and their precursor syndromes (CHIP, CCUS)
Measured: 10 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2026
- Study startSep 2026 (estimated)
- Primary completionJun 2036 (estimated)
- Study completionJun 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MDS (Myelodysplastic Syndrome)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Technische Universität Dresden
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07561385
- Sponsor's protocol ID
- Dresdner MDS-Register
- Status last verified
- Aug 2026
- First submitted
- 20 Apr 2026
- Last updated
- 27 Aug 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dresden MDS Registry With an Accompanying Biomaterial Collection
- ClinicalTrials.gov ID
- NCT07561385
- Acronym / sponsor ID
- Dresdner MDS-Register
- Conditions
- MDS (Myelodysplastic Syndrome), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome, CHIP, CCUS Clonal Cytopenia of Undetermined Significance
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Technische Universität DresdenUniversity, hospital or other
- Study start
- Sep 2026 (estimated)
- Primary completion
- Jun 2036 (estimated)
- Study completion
- Jun 2036 (estimated)
- First posted
- 1 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A registry for the study of the epidemiology, clinical course, and progression of myelodysplastic neoplasms (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN overlap syndromes), and their precursor syndromes (CHIP, CCUS)
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Diagnosis of myelodysplastic syndrome (MDS), MDS/MPN overlap syndrome, or evidence of a myelodysplastic precursor syndrome, defined as clonal hematopoiesis without cytopenia (clonal hematopoiesis of indeterminate potential, CHIP) or clonal hematopoiesis with cytopenia (clonal cytopenia of undetermined significance, CCUS) according to current WHO criteria
Key inclusion criteria (3 listed)
- Diagnosis of myelodysplastic syndrome (MDS), MDS/MPN overlap syndrome or evidence of myelodysplastic precursor syndrome, defined as clonal haematopoiesis without cytopenia (clonal haematopoiesis of indeterminate potential, CHIP) or clonal haematopoiesis with cytopenia (clonal cytopenia of undetermined significance, CCUS) in accordance with current WHO criteria
- Age ≥18 years
- Submission of a signed consent form for participation in the MDS Registry
Key exclusion criteria (2 listed)
- No exclusion criteria have been established with regard to the registry's primary objective. In particular, patients with comorbidities and those receiving non-curative treatment may be explicitly included in order to provide a realistic picture of actual care practices
- Inclusion in the registry is excluded in cases where a written consent form is not available or where patients are unable to understand the nature and implications of participating in this registry
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Collection of epidemiological data on MDS, MDS/MPN overlap syndromes and their precursor syndromes (CHIP, CCUS)
Time frame: 10 Years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
Related trials for MDS (Myelodysplastic Syndrome)
Not yet recruitingPhase 3
Efficacy and Safety of Maximum Labeled Dose Luspatercept in Lower-Risk Myelodysplastic Syndromes
Myelodysplastic Syndromes
RecruitingPhase 1
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Malignancy, Hematologic, Neoplasms, Hematologic
RecruitingObservational study
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease
RecruitingPhase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Active, not recruitingPhase 3
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
Paroxysmal Nocturnal Hemoglobinuria
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ekaterina Balaian, Dr. med. contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of MDS (Myelodysplastic Syndrome) and MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome, run by Technische Universität Dresden at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Katja Sockel, Dr. med. (+493514580, Katja.Sockel@ukdd.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Collection of epidemiological data on MDS, MDS/MPN overlap syndromes and their precursor syndromes (CHIP, CCUS) (time frame: 10 Years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026.